comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 00:09:26 - browse：74281

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： CRISPR gene editing developments we’re watching in 2024

WSS

Readout Newsletter: The latest on Moderna, Apellis, and Merck

NIH tests clinical research in primary care with $30 million program

Curing rare childhood diseases will falter unless Congress steps up

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Why health care costs have stayed mostly flat since 2010

Violet CEO on training clinicians to promote more inclusive care

hotspot

comprehensive

Wikipedia

Medicare details structure of new drug price negotiation program

My daughter's legacy lives on through her writing, phage therapy

BioMarin wins approval for gene therapy to treat hemophilia A

The system is set up to fail children with medical complexity

BioMarin wins approval for gene therapy to treat hemophilia A

Why health records don't always know when patients are dead

DIEP, the 'gold standard' of breast reconstruction, is under threat

CRISPR gene editing developments we’re watching in 2024

Duchenne breakthrough therapy leaves behind pioneering families

Moderna says combo Covid

focus

Carvykti CAR

Albert Bourla of Pfizer: worst biopharma CEO of 2023

California wildfire smoke linked to 52,000 early deaths, study says

Christmas in the PICU brings some surprising joy

HCA sued by state AG for quality issues at Mission Health

Teladoc has a new CEO, but challenges remain the same

focus

leisure time

entertainment

explore